BlueRock, RoslinCT partner to expand developer access to stem cell therapies

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

RoslinCT and BlueRock Therapeutics have entered a strategic partnership to broaden access to BlueRock’s clinical-grade induced pluripotent stem cell lines for cell therapy developers.

RoslinCT will add access to BlueRock’s clinical-grade lines alongside its own and will offer matched research-grade samples to prospective customers, while BlueRock will retain oversight of commercial licensing.

The companies completed a technical transfer of the cell lines to RoslinCT’s facilities, enabling RoslinCT to support customers with cell banking, process and analytical development, and manufacture of drug products for clinical and commercial use.

The expanded offering is intended to provide developers with a more comprehensive pathway to advance pluripotent cell-based therapies from early evaluation through to clinical and commercial supply, according to the company.

RoslinCT operates 22 purpose-built cGMP cell therapy suites in Edinburgh and Hopkinton, Massachusetts, and provides services across iPSC cell line development, gene editing, differentiation, and GMP manufacturing.

BlueRock is a clinical-stage cell therapy company with investigational programs including bemdaneprocel (BRT-DA01), in Phase III with RMAT and Fast Track designations, and OpCT-001 in Phase I with Fast Track designation.

Source: https://www.businesswire.com/news/home/20260708636768/en/RoslinCT-and-BlueRock-Therapeutics-Partner-to-Expand-Access-to-Clinical-Grade-Pluripotent-Cell-Lines-for-Cell-Therapy-Developers

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Novartis exits a BioArctic deal worth up to $802m

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE